About Dr. Chen Bobin
Dr. Chen Bobin (陈波斜) is a hematologist in the Department of Hematology at Huashan Hospital, Fudan University, with a focused subspecialty in difficult and refractory lymphoma — and in particular, central nervous system (CNS) lymphoma. CNS lymphoma is one of the rarest and most diagnostically and therapeutically challenging subtypes of lymphoma, requiring a specialist with deep experience in both hematological oncology and neuro-oncology. Dr. Chen's expertise in this niche makes him one of the few physicians in Shanghai — and in China — with the clinical depth to manage these cases comprehensively.
Huashan Hospital's unique position as both a leading hematology center and China's foremost neurology and neurosurgery hospital makes it the ideal institutional home for a CNS lymphoma specialist. Dr. Chen benefits from direct collaboration with Huashan's world-class neurology, neurosurgery, and neuroradiology teams — an integrated multidisciplinary environment that is essential for optimal CNS lymphoma management.
Clinical Expertise
- Primary CNS lymphoma (PCNSL) — comprehensive diagnosis and treatment of lymphoma arising in the brain, spinal cord, eyes (vitreoretinal lymphoma), or leptomeninges, without systemic disease
- Secondary CNS lymphoma — management of systemic lymphoma with CNS involvement or relapse, including leptomeningeal disease and parenchymal brain metastases from DLBCL and other aggressive subtypes
- Difficult and refractory lymphoma — individualized treatment strategies for patients with rare subtypes, unusual presentations, or disease that has failed multiple prior lines of therapy
- High-dose methotrexate (HD-MTX) based regimens — the cornerstone of PCNSL induction therapy; expertise in dosing, leucovorin rescue, and toxicity management
- Blood-brain barrier penetrating agents — rituximab (high-dose), thiotepa, cytarabine, and novel agents with CNS penetration for lymphoma treatment
- Autologous stem cell transplantation (ASCT) with thiotepa-based conditioning — consolidation strategy for eligible PCNSL patients achieving complete remission after induction
- Intrathecal chemotherapy — direct delivery of chemotherapy into the cerebrospinal fluid for leptomeningeal disease
- Vitreoretinal lymphoma — a rare ocular manifestation of CNS lymphoma requiring coordination with ophthalmology and intravitreal therapy
Why Dr. Chen Bobin?
Primary CNS lymphoma is a disease where subspecialty expertise is not a luxury — it is a necessity. PCNSL accounts for only 3–4% of all brain tumors and fewer than 1% of all lymphomas, meaning that most oncologists and even most hematologists see only a handful of cases in their careers. The treatment protocols are complex, the toxicity management is demanding, and the consequences of suboptimal treatment — including neurotoxicity from whole-brain radiation or inadequate CNS penetration of chemotherapy — can be severe and irreversible.
Dr. Chen's focused experience in CNS lymphoma at Huashan Hospital — where the neurology and neurosurgery infrastructure is among the best in China — means that patients receive care from a specialist who has seen enough cases to recognize atypical presentations, navigate diagnostic uncertainty, and design treatment plans that balance efficacy with the unique toxicity profile of CNS-directed therapy.
For patients with systemic lymphoma who develop CNS relapse — one of the most feared complications of aggressive B-cell lymphoma — Dr. Chen's expertise in secondary CNS lymphoma management provides a critical resource that is not available at most oncology centers.
Hospital: Huashan Hospital, Fudan University
Huashan Hospital is China's most renowned neurology and neurosurgery center, and one of its top academic medical institutions. For CNS lymphoma — a disease that sits at the intersection of hematology and neuro-oncology — Huashan's unique combination of world-class hematology and neuroscience expertise makes it the optimal treatment environment in China. The hospital's neuroradiology department provides advanced MRI protocols essential for CNS lymphoma diagnosis and response assessment, and its neurosurgery team can perform stereotactic brain biopsies when tissue diagnosis is required. This integrated infrastructure is available to Dr. Chen's patients through direct interdepartmental collaboration.
About CNS Lymphoma
Central nervous system lymphoma is a rare and aggressive malignancy that requires prompt diagnosis and specialized treatment. Key facts for international patients:
- Primary CNS lymphoma (PCNSL): 95% are DLBCL; presents with focal neurological deficits, cognitive changes, personality changes, or elevated intracranial pressure; diagnosis requires brain MRI with contrast and stereotactic biopsy
- Diagnosis: stereotactic brain biopsy is the gold standard; CSF cytology and flow cytometry, vitreous biopsy (if ocular involvement), and aqueous humor analysis are complementary
- Corticosteroids: dramatically reduce tumor size and symptoms but obscure pathological diagnosis — biopsy should be performed before steroid administration whenever possible
- First-line treatment: HD-MTX-based combination chemotherapy (MATRix: methotrexate + cytarabine + thiotepa + rituximab) is the current international standard for eligible patients
- Consolidation: autologous stem cell transplantation with thiotepa-based conditioning is preferred over whole-brain radiation for patients achieving complete remission, due to superior neurocognitive outcomes
- Relapsed/refractory PCNSL: BTK inhibitors (ibrutinib, zanubrutinib) show significant activity; CAR-T cell therapy is under active investigation; whole-brain radiation remains an option for patients ineligible for other approaches
- Prognosis: 5-year survival of 30–40% with optimal treatment at specialized centers; significantly worse with suboptimal therapy or delayed diagnosis
- Immunocompromised patients: EBV-associated CNS lymphoma occurs in HIV-positive patients and transplant recipients; requires different diagnostic and treatment approach
What to Prepare Before Your Consultation
To enable Dr. Chen's team to conduct a thorough remote case review, international patients should prepare:
- Brain MRI with gadolinium contrast (DICOM format, within 4 weeks — CNS lymphoma can change rapidly)
- Spine MRI if leptomeningeal involvement is suspected
- CSF analysis results: cytology, flow cytometry, protein, glucose, and IgH gene rearrangement if performed
- Pathology report from brain biopsy with full IHC panel (CD20, CD3, CD10, BCL6, MYC, Ki-67, MUM1/IRF4)
- Ophthalmology report if visual symptoms are present (vitreoretinal lymphoma evaluation)
- Systemic staging: CT of chest, abdomen, and pelvis; bone marrow biopsy if not yet performed
- Complete treatment history if previously treated
- Current neurological symptoms and performance status
How CMCS Can Help
China Medical Concierge Shanghai (CMCS) coordinates access to Dr. Chen Bobin and the Huashan Hospital hematology and neuro-oncology team for international patients with CNS lymphoma. Our services include:
- Remote case review and pre-consultation assessment before you travel
- Priority appointment scheduling with Dr. Chen's team at Huashan Hospital
- Full translation of neuroimaging reports, pathology, CSF results, and treatment plans
- In-hospital accompaniment by a dedicated English-speaking case manager
- Coordination with Huashan's neurology, neurosurgery, and neuroradiology teams as needed
- Accommodation, airport transfer, and logistics coordination in Shanghai
- Post-discharge follow-up and remote consultation support after returning home
Contact us to begin your case review:
📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com
0 comentarios